GLPwatch

[Severe gastroparesia associated with the use of GLP-1 receptor agonists for weight loss].

Rev Gastroenterol Peru · 2024

Last updated 2026-05-28

A 69-year-old woman with a history of peptic ulcers and NSAID use developed severe gastroparesis (a condition where the stomach empties too slowly) after taking semaglutide, a GLP-1 receptor agonist used for weight loss. Her symptoms improved and resolved with supportive care, and the case highlights a potential risk of GLP-1 drugs in patients undergoing procedures requiring sedation.

AI summary of the abstract below.

JournalRev Gastroenterol Peru, 2024
Citations1
Relative citation ratio0.31
NIH percentile19
Molecules
Conditions studied Gastroparesis

Abstract

Initially developed as medications for diabetes mellitus, GLP-1 agonists have gained much popularity in the treatment of obesity and weight loss. The present case describes a 69-year-old woman with a history of peptic ulcer and use of NSAIDs, who presented with abdominal pain and oral intolerance refractory to conventional management, for which an upper digestive endoscopy was performed, diagnosing severe gastroparesis. Asking more about the story, revealed surreptitious use of semaglutide. She continued with supportive therapy and the symptoms resolved spontaneously. The present case report aims to warn of the potential risks of the use of GLP-1 analogues in the context of endoscopy with sedation.

Verbatim abstract via PubMed 38734915 ↗